GE Healthcare is opening a biotechnology manufacturing centre in the UK which will produce a fibre-based purification platform that, it says, could improve the efficiency in the purification steps during the manufacturing of biopharmaceuticals, gene therapies and viral vectors.
The platform comprises material with a unique proprietary structure. This has the potential to significantly improve process speed, flexibility and robustness during purification, a key step in the manufacturing of biopharmaceuticals.
Additional products will also be produced at the centre to serve both laboratory and clinical applications.
The fibre-based purification products will be prepared in facility at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, before being further processed and finished in GE Healthcare’s existing manufacturing facility in Cardiff, Wales.
“This technology will bring real efficiency and productivity advantages for biopharmaceutical manufacturers as they move towards integrated, connected or continuous operations,” says Olivier Loeillot, General Manager, BioProcess at GE Healthcare Life Sciences.
“The fibre-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.”